Evaluation of Efficacy of a Cashew Apple Extract on Weight Management and Associated Metabolic Risk Factors in Overweight/Obese Volunteers

Evaluation of Efficacy and Safety of a Cashew Apple Extract on Weight Management and Associated Metabolic Risk Factors in Overweight/Obese Volunteers: a Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02493140

Enrollment

Registered

2015-07-09

Start date

2015-07-31

Completion date

2016-02-29

Last updated

2015-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weight Loss

Keywords

Weight management, cashew apple extract, overweight

Brief summary

The purpose of this study is to assess the efficacy and safety of a cashew apple extract on weight management and associated metabolic risk factors in overweight/obese volunteers, versus placebo, after 12 weeks of treatment.

Interventions

DIETARY_SUPPLEMENTCashew apple extract (Cashewin)

6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks

DIETARY_SUPPLEMENTPlacebo

6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* 27 ≤ BMI ≤ 35 kg/m² * Abdominal obesity * Acceptance to adhere to diet and physical activity recommendations while maintaining global lifestyle habits * Stable body weight (\<5% variation) within the last 3 months prior to screening

Exclusion criteria

* Allergy to nuts and products thereof and allergy to mango fruit * Type I or II diabetes * Smokers * Severe chronic diseases * History of bariatric surgery and eating disorders * Use of weight management products or medications which could affect nutrients absorption, lipids or carbohydrates metabolism

Design outcomes

Primary

Measure	Time frame
Body weight reduction	12 weeks

Secondary

Measure	Time frame
Body fat variation	6 and 12 weeks
BMI variation	6 and 12 weeks
Waist and hip circumferences variation	6 and 12 weeks
Fasting glycemia variation	12 weeks
Fasting insulinemia variation	12 weeks
Body weight variation	6 weeks and 12 weeks
Variation of glycemia 2h post glucose solution intake	12 weeks
Blood lipids (total cholesterol, HDL, LDL, triglycérides) variation	12 weeks
CRPus variation	12 weeks
Systolic and diastolic blood pressure variation	6 and 12 weeks
Safety (blood parameters measurements: urea, creatinine, ASAT, ALAT) with adverse events recording	12 weeks
HOMA-IR index variation	12 weeks

Countries

France

Contacts

Primary ContactMarie Peytavy-Izard

m.peytavy@dialpha.com+33467404419

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026